Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade

(2019) Lynda Vuong et al.   CANCER RESEARCH

Role of Galectins in Tumors and in Clinical Immunotherapy

(2018) Feng-Cheng Chou et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Galectins at a glance

(2018) Ludger Johannes et al.   JOURNAL OF CELL SCIENCE

Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration

(2017) Monica Gordon-Alonso et al.   Nature Communications

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

(2016) Takaaki Tokito et al.   EUROPEAN JOURNAL OF CANCER

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments

(2016) Ana Carolina Ferreira Cardoso et al.   Frontiers in Oncology

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages

(2011) Ruder Novak et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS